Rationale and design of a phase II trial of dacomitinib in advanced non-small cell lung cancer patients with uncommon epidermal growth factor receptor mutations: a prospective and single arm study (DANCE study).
Clinical features and treatment outcome of non-small cell lung cancer (NSCLC) patients with uncommon or complex epidermal growth factor receptor (EGFR) mutations.
Oncotarget
Frega, Stefano S; Lorenzi, Martina M; Fassan, Matteo M; Indraccolo, Stefano S; Calabrese, Fiorella F; Favaretto, Adolfo A; Bonanno, Laura L; Polo, Valentina V; Zago, Giulia G; Lunardi, Francesca F; Attili, Ilaria I; Pavan, Alberto A; Rugge, Massimo M; Guarneri, Valentina V; Conte, PierFranco P; Pasello, Giulia G